Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: This is a narrative review, investigating the antioxidant properties of drugs used in the management of diabetes, and discusses whether these antioxidant effects contribute to, confound, or conceal the effects of antioxidant therapy. METHODS: A systematic search for articles reporting trials, or observational studies on the antioxidant effect of drugs used in the treatment of diabetes in humans or animals was performed using Web of Science, PubMed, and Ovid. Data were extracted, including data on a number of subjects, type of treatment (and duration) received, and primary and secondary outcomes. The primary outcomes were reporting on changes in biomarkers of antioxidants concentrations and secondary outcomes were reporting on changes in biomarkers of oxidative stress. RESULTS: Diabetes Mellitus is a disease characterized by increased oxidative stress. It is often accompanied by a spectrum of other metabolic disturbances, including elevated plasma lipids, elevated uric acid, hypertension, endothelial dysfunction, and central obesity. This review shows evidence that some of the drugs in diabetes management have both in vivo and in vitro antioxidant properties through mechanisms such as scavenging free radicals and upregulating antioxidant gene expression. CONCLUSION: Pharmaceutical agents used in the treatment of type 2 diabetes has been shown to exert an antioxidant effect..
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives
Chen, L., Magliano, D. J., & Zimmet, P. Z. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.183 · Cited by 2,227 · cited 1×
“Sitagliptin (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one C16H15F6N5O Inhibits dipeptidylpeptidase-4, increases insulin secretion and lowers glucagon secretion.”
BackgroundCellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance
Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R. W., Washko, P. W., Dhariwal, K. R., Park, J. B., Lazarev, A., Graumlich, J. F., King, J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3704 · Cited by 1,325
Criteria and recommendations for vitamin C intake
Levine, M. (1999) · JAMA · doi:10.1001/jama.281.15.1415 · Cited by 559
Association of Nitrotyrosine Levels With Cardiovascular Disease and Modulation by Statin Therapy
Shishehbor, M. H., Aviles, R. J., Brennan, M.-L., Fu, X., Goormastic, M., Pearce, G. L., Gokce, N., Keaney, J. F., Penn, M. S., Sprecher, D. L., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1675 · Cited by 464 · cited 1×
“Atorvastatin Subjects without clinical evidence of carotid artery disease, active liver disease and renal insufficiency and with LDL-C≥ 130 mg/dl [66] Atorvastatin (10 mg/day) [n = 35] 12 weeks Plasma levels of protein-bound chlorotyrosine, nitrotyrosine, dityrosine, and orthotyrosine, plasma CRP.”
BackgroundCurrent views on type 2 diabetes
Lin, Y., & Sun, Z. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0260 · Cited by 457 · cited 7×
“Type 2 DM patients without macroangiopathy [68] Atorvastatin (10 mg/day), [n = 15] Vitamin C (2 g/day), [n = 13] No treatment control, [n = 14] 4 weeks Serum IL-6, TNF-α, sVCAM-1, CRP, and ADMA.”
InfluentialSorrentino, S. A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F. H., Mueller, M., Horváth, T., Doerries, C., Heinemann, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.108.836346 · Cited by 402 · cited 1×
“Niacin Type 2 DM patients with reduced HDL cholesterol levels and metabolic syndrome [85] Extended-release niacin from 500 mg/day for 3 months, with escalation to 1000 mg/day every month; [n = 15] Healthy controls [n = 10] Endothelial superoxide production, NADPH oxidase activity, and lipid oxidation of HDL as measure…”
Method
Cited by
Reactive oxygen species (ROS) in macrophage activation and function in diabetes
Rendra, E., Riabov, V., Mossel, D. M., Sevastyanova, T., Harmsen, M. C., & Kzhyshkowska, J. (2019) · Immunobiology · doi:10.1016/j.imbio.2018.11.010 · Cited by 636
The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor
D’Oria, R., Schipani, R., Leonardini, A., Natalicchio, A., Perrini, S., Cignarelli, A., Laviola, L., & Giorgino, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5732956 · Cited by 376
Unuofin, J. O., & Lebelo, S. L. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1356893 · Cited by 308
Shabalala, S. C., Johnson, R., Basson, A. K., Ziqubu, K., Hlengwa, N., Mthembu, S. X. H., Mabhida, S. E., Mazibuko-Mbeje, S. E., Hanser, S., Cirilli, I., et al. (2022) · Antioxidants · doi:10.3390/antiox11102071 · Cited by 102
“Thus, it is essential to recognize antioxidant therapies as a potential strategy to combat lipid peroxidation and oxidative stress during the development of diverse chronic diseases, including T2D [20].”
BackgroundNuñez-Selles, A. J., Nuñez-Musa, R. A., & Guillen-Marmolejos, R. A. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1611842 · Cited by 51
Metadata
- Authors
- Choi, S. W., & Ho, C. K.
- Venue
- Redox Report
- Publisher
- Informa UK Limited
- Published
- 2017-05-17
- Volume
- 23
- Issue
- 1
- Pages
- 1-24
- ISSN
- 1351-0002 (ISSN-L)
- 1743-2928
- OpenAlex
- W2615463995
- Cited by
- 57
- References
- 16
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy? https://app.cochat.ai/papers/10.1080/13510002.2017.1324381
- The paper
- Choi, S. W., & Ho, C. K. (2018). Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy? Redox Report. https://doi.org/10.1080/13510002.2017.1324381
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.